Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy S Bailey

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Diabetes, Obesity & Metabolism|October 26, 2023
Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trialViral N Shah, Amer Al-Karadsheh, Cathy Barnes, et al.
Journal of Diabetes Science and Technology|February 29, 2024
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X TrialViral N Shah, Amer Al-Karadsheh, Cathy Barnes, et al.
Diabetes Technology & Therapeutics|February 14, 2022
Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with DiabetesSatish K Garg, Mark Kipnes, Kristin Castorino, et al.
Diabetes Technology & Therapeutics|January 31, 2018
A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE IIMark P Christiansen, Leslie J Klaff, Ronald Brazg, et al.
JAMA|February 24, 2021
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical TrialThomas A Wadden, Timothy S Bailey, Liana K Billings, et al.
Diabetes Technology & Therapeutics|September 13, 2021
Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE StudySatish K Garg, David Liljenquist, Bruce Bode, et al.
Diabetes Technology & Therapeutics|July 30, 2020
Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin AloneThomas Danne, Vijay N Joish, Marion Afonso, et al.
Journal of Diabetes Science and Technology|February 4, 2026
In Support of Venous Glucose as a Reference Matrix for Evaluating Continuous Glucose Monitoring AccuracyDavid C Klonoff, Timothy S Bailey, Tadej Battelino, et al.
Diabetes Technology & Therapeutics|December 27, 2018
Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 DiabetesGregory P Forlenza, Orit Pinhas-Hamiel, David R Liljenquist, et al.
Diabetes Care|June 26, 2018
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 StudyJohn B Buse, Satish K Garg, Julio Rosenstock, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Diabetes, Obesity & Metabolism|October 26, 2023
Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trialViral N Shah, Amer Al-Karadsheh, Cathy Barnes, et al.
Journal of Diabetes Science and Technology|February 29, 2024
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X TrialViral N Shah, Amer Al-Karadsheh, Cathy Barnes, et al.
Diabetes Technology & Therapeutics|February 14, 2022
Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with DiabetesSatish K Garg, Mark Kipnes, Kristin Castorino, et al.
Diabetes Technology & Therapeutics|January 31, 2018
A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE IIMark P Christiansen, Leslie J Klaff, Ronald Brazg, et al.
JAMA|February 24, 2021
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical TrialThomas A Wadden, Timothy S Bailey, Liana K Billings, et al.
Diabetes Technology & Therapeutics|September 13, 2021
Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE StudySatish K Garg, David Liljenquist, Bruce Bode, et al.
Diabetes Technology & Therapeutics|July 30, 2020
Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin AloneThomas Danne, Vijay N Joish, Marion Afonso, et al.
Journal of Diabetes Science and Technology|February 4, 2026
In Support of Venous Glucose as a Reference Matrix for Evaluating Continuous Glucose Monitoring AccuracyDavid C Klonoff, Timothy S Bailey, Tadej Battelino, et al.
Diabetes Technology & Therapeutics|December 27, 2018
Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 DiabetesGregory P Forlenza, Orit Pinhas-Hamiel, David R Liljenquist, et al.
Diabetes Care|June 26, 2018
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 StudyJohn B Buse, Satish K Garg, Julio Rosenstock, et al.
Pageof 11